

\$2.5B +7%

ON OPERATIONAL BASIS**

**Adjusting for the impact of foreign exchange, generic competition for U.S. cyclophosphamide and previously communicated select strategic product exits

\$0.58 +61%

INCREASES FULL-YEAR 2017 FINANCIAL OUTLOOK

WORLDWIDE NET SALES

+4-5%

ON OPERATIONAL BASIS

Versus ~4% operational sales growth guidance issued 2/1/17

ADJUSTED EARNINGS PER DILUTED SHARE*

\$2.20-\$2.28

+\$0.10

Increase on both ends of the range versus guidance issued 2/1/17



“Encouraged by a solid start to 2017 and the ongoing momentum of our business transformation initiatives, we are raising our full-year sales and earnings outlook. We are driving growth through disciplined execution and particular strength across our U.S. businesses. We will continue to invest in evolving our portfolio through the introduction of innovative products and technologies along with geographic expansion to deliver future growth.”

José (Joe) E. Almeida